AGEN
Price
$3.48
Change
+$0.33 (+10.48%)
Updated
Jan 17 closing price
Capitalization
82.17M
HMTXF
Price
$0.21
Change
+$0.03 (+15.79%)
Updated
Jan 17 closing price
Capitalization
30.28M
Ad is loading...

AGEN vs HMTXF

Header iconAGEN vs HMTXF Comparison
Open Charts AGEN vs HMTXFBanner chart's image
Agenus
Price$3.48
Change+$0.33 (+10.48%)
Volume$378.39K
Capitalization82.17M
Hemostemix
Price$0.21
Change+$0.03 (+15.79%)
Volume$70.25K
Capitalization30.28M
AGEN vs HMTXF Comparison Chart
Loading...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HMTXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGEN vs. HMTXF commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a Hold and HMTXF is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (AGEN: $3.48 vs. HMTXF: $0.22)
Brand notoriety: AGEN and HMTXF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGEN: 72% vs. HMTXF: 323%
Market capitalization -- AGEN: $82.17M vs. HMTXF: $30.28M
AGEN [@Biotechnology] is valued at $82.17M. HMTXF’s [@Biotechnology] market capitalization is $30.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 0 FA rating(s) are green whileHMTXF’s FA Score has 1 green FA rating(s).

  • AGEN’s FA Score: 0 green, 5 red.
  • HMTXF’s FA Score: 1 green, 4 red.
According to our system of comparison, HMTXF is a better buy in the long-term than AGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 4 TA indicator(s) are bullish while HMTXF’s TA Score has 5 bullish TA indicator(s).

  • AGEN’s TA Score: 4 bullish, 4 bearish.
  • HMTXF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, HMTXF is a better buy in the short-term than AGEN.

Price Growth

AGEN (@Biotechnology) experienced а +11.72% price change this week, while HMTXF (@Biotechnology) price change was +28.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

AGEN is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGEN($82.2M) has a higher market cap than HMTXF($30.3M). HMTXF YTD gains are higher at: 191.882 vs. AGEN (27.007). HMTXF has higher annual earnings (EBITDA): -1.96M vs. AGEN (-77.64M). AGEN has more cash in the bank: 44.8M vs. HMTXF (63.3K). HMTXF has less debt than AGEN: HMTXF (4.77M) vs AGEN (78.4M). AGEN has higher revenues than HMTXF: AGEN (160M) vs HMTXF (0).
AGENHMTXFAGEN / HMTXF
Capitalization82.2M30.3M271%
EBITDA-77.64M-1.96M3,966%
Gain YTD27.007191.88214%
P/E Ratio0.46N/A-
Revenue160M0-
Total Cash44.8M63.3K70,774%
Total Debt78.4M4.77M1,642%
FUNDAMENTALS RATINGS
AGEN vs HMTXF: Fundamental Ratings
AGEN
HMTXF
OUTLOOK RATING
1..100
3750
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6234
P/E GROWTH RATING
1..100
94100
SEASONALITY SCORE
1..100
4275

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HMTXF's Valuation (4) in the null industry is significantly better than the same rating for AGEN (97) in the Biotechnology industry. This means that HMTXF’s stock grew significantly faster than AGEN’s over the last 12 months.

HMTXF's Profit vs Risk Rating (93) in the null industry is in the same range as AGEN (100) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to AGEN’s over the last 12 months.

HMTXF's SMR Rating (100) in the null industry is in the same range as AGEN (100) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to AGEN’s over the last 12 months.

HMTXF's Price Growth Rating (34) in the null industry is in the same range as AGEN (62) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's P/E Growth Rating (94) in the Biotechnology industry is in the same range as HMTXF (100) in the null industry. This means that AGEN’s stock grew similarly to HMTXF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENHMTXF
RSI
ODDS (%)
N/A
Bearish Trend 12 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
89%
Bearish Trend 12 days ago
82%
Momentum
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 12 days ago
76%
MACD
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 12 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 12 days ago
54%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 12 days ago
55%
Advances
ODDS (%)
Bullish Trend 13 days ago
84%
Bullish Trend 18 days ago
80%
Declines
ODDS (%)
Bearish Trend 21 days ago
89%
N/A
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
90%
Aroon
ODDS (%)
Bearish Trend 12 days ago
86%
Bearish Trend 12 days ago
81%
View a ticker or compare two or three
Ad is loading...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HMTXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SUSA124.421.05
+0.85%
iShares MSCI USA ESG Select ETF
JOET39.360.33
+0.84%
Virtus Terranova US Quality Momentum ETF
NANR54.850.40
+0.73%
SPDR S&P® North American Natural Res ETF
JHCB21.000.01
+0.02%
JHancock Corporate Bond ETF
SPAX20.06-0.12
-0.60%
Robinson Alternative Yld Pr-Mrgr SPACETF

HMTXF and

Correlation & Price change

A.I.dvisor tells us that HMTXF and DMAC have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HMTXF and DMAC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HMTXF
1D Price
Change %
HMTXF100%
+14.67%
DMAC - HMTXF
22%
Poorly correlated
+0.71%
BIVI - HMTXF
21%
Poorly correlated
+0.45%
AGEN - HMTXF
21%
Poorly correlated
+10.48%
DVHGF - HMTXF
21%
Poorly correlated
N/A
FDMT - HMTXF
12%
Poorly correlated
-2.14%
More